SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Medline Inc. (MDLN) trades at a trailing P/E of 31.2, forward P/E of 32.5. Trailing earnings yield is 3.21%, forward earnings yield 3.07%. PEG 13.02. Graham Number is $27.59.
Criteria proven by this page:
- VALUE (46/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- PEG Ratio 13.02 — above 2.0 suggests expensive relative to earnings growth.
- Trailing Earnings Yield 3.21% — roughly competitive with bond yields (~4.3%), moderate risk-reward.
- Analyst consensus target $48.59 (+1.9% upside) — modest upside expected.
Overall SharesGrow Score: 66/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
46/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — MDLN
Valuation Multiples
P/E (TTM)31.2
Forward P/E32.5
PEG Ratio13.02
Forward PEG13.02
P/B Ratio3.36
P/S Ratio1.27
EV/EBITDA15.0
Per Share Data
EPS (TTM)$1.42
Forward EPS (Est.)$1.47
Book Value / Share$23.75
Revenue / Share$35.01
FCF / Share$2.15
Yields & Fair Value
Earnings Yield3.21%
Forward Earnings Yield3.07%
Dividend Yield0.00%
Graham Number$27.59
SharesGrow IV$33.70 (-29.3%)
Analyst Target$48.59 (+1.9%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2022 |
-1,290.9 |
0.00 |
0.00 |
1.50 |
- |
| 2023 |
137.9 |
-0.13 |
1.90 |
1.39 |
- |
| 2024 |
26.9 |
0.07 |
1.95 |
1.27 |
- |
| 2025 |
29.4 |
-4.97 |
3.18 |
1.20 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2022 |
$-0.03 |
$21.45B |
$-25M |
-0.1% |
| 2023 |
$0.30 |
$23.23B |
$234M |
1% |
| 2024 |
$1.52 |
$25.51B |
$1.2B |
4.7% |
| 2025 |
$1.43 |
$28.43B |
$1.16B |
4.1% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$1.47 |
$1.01 – $1.56 |
$30.88B |
$30.83B – $30.92B |
15 |
| 2027 |
$1.65 |
$1.24 – $1.77 |
$33.25B |
$33.16B – $33.34B |
15 |
| 2028 |
$1.89 |
$1.77 – $2.11 |
$35.86B |
$35.86B – $35.87B |
9 |
| 2029 |
$2.12 |
$2.11 – $2.14 |
$38.44B |
$38.24B – $38.73B |
3 |
| 2030 |
$2.39 |
$2.37 – $2.41 |
$41.06B |
$40.84B – $41.37B |
3 |
